Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian D Davis

Showing results (101-110 of 282) with videos related to

Pageof 29
Sort By:
The Journal of Sexual Medicine|February 9, 2016
Health-Related Quality of Life, Psychological Distress, and Sexual Changes Following Prostate Cancer: A Comparison of Gay and Bisexual Men with Heterosexual MenJane M Ussher, Janette Perz, Andrew Kellett, et al.
The Prostate|October 23, 2008
Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapyMarcus P Kelly, Sze Ting Lee, F-T Lee, et al.
BJU International|September 9, 2014
The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group--a new co-operative cancer trials group in genitourinary oncologyShomik Sengupta, Peter Grimison, Dickon Hayne, et al.
BJU International|November 5, 2025
Target trial emulation of early docetaxel and enzalutamide for metastatic hormone-sensitive prostate cancerYu Yang Soon, Ian C Marschner, I Manjula Schou, et al.
The Medical Journal of Australia|May 26, 2018
Active surveillance of men with low risk prostate cancer: evidence from the Prostate Cancer Outcomes Registry-VictoriaMelanie A Evans, Jeremy L Millar, Arul Earnest, et al.
JAMA Network Open|September 17, 2024
Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate CancerYu Yang Soon, Ian C Marschner, Manjula Schou, et al.
BJU International|December 21, 2012
Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysisBaerin B Houghton, Venu Chalasani, Dickon Hayne, et al.
Cancer Immunology, Immunotherapy : CII|February 18, 2009
Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cellsCraig Gedye, Juliet Quirk, Judy Browning, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2008
Predicting clinical outcome through molecular profiling in stage III melanomaThomas John, Michael A Black, Tumi T Toro, et al.
American Journal of Clinical Oncology|April 14, 2009
An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancerCarmel Pezaro, Mark A Rosenthal, Howard Gurney, et al.
Pageof 29

Showing results (101-110 of 282) with videos related to

Sort By:
Pageof 29
The Journal of Sexual Medicine|February 9, 2016
Health-Related Quality of Life, Psychological Distress, and Sexual Changes Following Prostate Cancer: A Comparison of Gay and Bisexual Men with Heterosexual MenJane M Ussher, Janette Perz, Andrew Kellett, et al.
The Prostate|October 23, 2008
Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapyMarcus P Kelly, Sze Ting Lee, F-T Lee, et al.
BJU International|September 9, 2014
The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group--a new co-operative cancer trials group in genitourinary oncologyShomik Sengupta, Peter Grimison, Dickon Hayne, et al.
BJU International|November 5, 2025
Target trial emulation of early docetaxel and enzalutamide for metastatic hormone-sensitive prostate cancerYu Yang Soon, Ian C Marschner, I Manjula Schou, et al.
The Medical Journal of Australia|May 26, 2018
Active surveillance of men with low risk prostate cancer: evidence from the Prostate Cancer Outcomes Registry-VictoriaMelanie A Evans, Jeremy L Millar, Arul Earnest, et al.
JAMA Network Open|September 17, 2024
Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate CancerYu Yang Soon, Ian C Marschner, Manjula Schou, et al.
BJU International|December 21, 2012
Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysisBaerin B Houghton, Venu Chalasani, Dickon Hayne, et al.
Cancer Immunology, Immunotherapy : CII|February 18, 2009
Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cellsCraig Gedye, Juliet Quirk, Judy Browning, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2008
Predicting clinical outcome through molecular profiling in stage III melanomaThomas John, Michael A Black, Tumi T Toro, et al.
American Journal of Clinical Oncology|April 14, 2009
An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancerCarmel Pezaro, Mark A Rosenthal, Howard Gurney, et al.
Pageof 29